Dainippon Sumitomo Pharma announces BBI608 Clinical Study Data to be presented at the 2013 ASCO Annual Meeting

Osaka, Japan, May 16, 2013 – Dainippon Sumitomo Pharma Co., Ltd. (DSP) (Headquarters: Osaka, Japan; President: Masayo Tada) announces that the following clinical study data on BBI608 will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 to June 4, 2013.

Abstract Number: #2542
Title: A Dose Escalation Phase 1 Study of a First-In-Class Cancer Stemness Inhibitor in Patients with Advanced Malignancies
Date and Time: 08:00 ~ 11:45 Monday, June 3, 2013 (Local Time)
Program: General Poster Session: Developmental Therapeutics
Presentation Venue: S Hall A2 Brd. 2C
Outline of Results: 41 adult patients with advanced cancer were dosed from 20 mg to 2000 mg/day with adverse events being generally mild. MTD was not reached. 17/26 patients evaluable for tumor response, achieved stable disease (SD), for a disease control rate (DCR) of 65%. In the subset of patients with colorectal cancer (CRC) (N=18), SD was seen in 8/12 evaluable (67%). Median progression free survival (PFS) of 14 weeks and median overall survival (OS) of 47 weeks were observed in evaluable CRC patients.

DSP announced the abstract number and the title on May 9, 2013.

(Reference)
BBI608 is an anti-cancer drug created and currently under development (Phase 3 in North America) by Boston Biomedical Inc. BBI608 has a novel mechanism that shows anti-tumor effects by targeting cancer stem cells (cancer cells with stem cell-like properties) as well as other heterogeneous cancer cells. By targeting cancer stem cells in addition to heterogeneous cancer cells, efficacy is expected in the current challenges in therapy against cancer, such as treatment resistance, metastasis and recurrence.